Medications for weight loss and diabetes linked to higher risk of stomach paralysis.

New data from real-world usage of injected medications for treating diabetes and obesity suggests a rare yet significant side effect: stomach paralysis.

At least three recent studies, drawing from extensive patient records, indicate a heightened risk of gastroparesis among individuals using GLP-1 agonists compared to those who do not.

While these findings have not undergone external expert scrutiny or publication in medical journals, they provide preliminary insights.

Two studies were presented at the Digestive Disease Week 2024 conference in Washington on Saturday, with the third scheduled for presentation on Monday.